Cart
sales@molnova.com
FLAVOKAVAIN A(P)
CAS No. 37951-13-6
FLAVOKAVAIN A(P)( —— )
Catalog No. M20438 CAS No. 37951-13-6
FLAVOKAVAIN A(P) a novel chalcone from kava extract induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 54 | In Stock |
|
| 5MG | 37 | In Stock |
|
| 10MG | 68 | In Stock |
|
| 25MG | 114 | In Stock |
|
| 50MG | 165 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFLAVOKAVAIN A(P)
-
NoteResearch use only, not for human use.
-
Brief DescriptionFLAVOKAVAIN A(P) a novel chalcone from kava extract induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice.
-
DescriptionFLAVOKAVAIN A(P) a novel chalcone from kava extract induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetP450
-
RecptorCYP450
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number37951-13-6
-
Formula Weight314.33
-
Molecular FormulaC18H18O5?
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (79.53 mM)
-
SMILESCOc1ccc(cc1)\C=C\C(=O)c1c(O)cc(OC)cc1OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Niu L Ding L Lu C et al. Flavokawain A Inhibits Cytochrome P450 in in vitro Metabolic and Inhibitory Investigations[J]. Journal of Ethnopharmacology 2016:S0378874116304007.
molnova catalog
related products
-
Xanthatin
Xanthatin has antibacterial and antifungal activies against MRSA.
-
AS1810722
AS1810722 is an orally active and potent STAT6 inhibitor(IC50 :1.9 nM). AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research.
-
Bergapten
5-Methoxypsoralen, a naturally occurring linear furocoumarin, has been successfully used in combination with ultraviolet (UV) A irradiation [psoralen plus UV (PUVA)] to manage psoriasis and vitiligo.
